Gilead Sciences Secures Global Rights to PepStar’s Oral IL-23 Inhibitor in Landmark $1.275 Billion Deal to Transform IBD Treatment
SAN FRANCISCO — In a major strategic play to expand its footprint in immunology, Gilead…
Tag: gilead
Gilead Sciences and Vir Biotechnology Join Forces in Multi-Billion-Dollar Deal to Advance Next-Generation Solid Tumour Therapies
LONDON/FOSTER CITY — In a major strategic play highlighting the pharmaceutical industry’s surging interest in…
